Fjarde AP Fonden Fourth Swedish National Pension Fund Trims Stock Position in Ralliant Corporation $RAL

Fjarde AP Fonden Fourth Swedish National Pension Fund trimmed its holdings in shares of Ralliant Corporation (NYSE:RAL) by 93.0% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,305 shares of the company’s stock after selling 17,468 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in Ralliant were worth $57,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of RAL. ORG Partners LLC purchased a new stake in Ralliant during the second quarter valued at about $70,000. Nordea Investment Management AB acquired a new position in shares of Ralliant in the 2nd quarter valued at about $29,477,000. Cullen Frost Bankers Inc. purchased a new stake in shares of Ralliant during the 2nd quarter worth about $144,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new stake in Ralliant during the 2nd quarter worth approximately $1,410,000. Finally, Boston Partners purchased a new position in Ralliant in the second quarter valued at approximately $63,656,000.

Analyst Ratings Changes

Several equities research analysts have issued reports on RAL shares. Barclays boosted their price objective on shares of Ralliant from $59.00 to $60.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 7th. Truist Financial assumed coverage on shares of Ralliant in a research report on Friday, December 12th. They set a “buy” rating and a $62.00 price target for the company. Citigroup upgraded Ralliant from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $53.00 to $61.00 in a research note on Monday, December 8th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Ralliant in a research report on Monday, December 29th. Finally, Oppenheimer raised their target price on Ralliant from $55.00 to $60.00 and gave the company an “outperform” rating in a report on Monday, December 15th. Six research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $58.00.

Ralliant Stock Down 0.7%

RAL stock opened at $53.51 on Tuesday. The business’s 50 day simple moving average is $50.27. Ralliant Corporation has a 52-week low of $40.70 and a 52-week high of $55.08. The stock has a market cap of $6.04 billion and a P/E ratio of 42.13. The company has a quick ratio of 1.03, a current ratio of 1.49 and a debt-to-equity ratio of 0.39.

Ralliant (NYSE:RAL) last released its earnings results on Wednesday, November 5th. The company reported $0.60 EPS for the quarter, beating the consensus estimate of $0.58 by $0.02. The business had revenue of $529.10 million for the quarter, compared to analysts’ expectations of $519.14 million. Ralliant has set its Q4 2025 guidance at 0.620-0.680 EPS.

Ralliant Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, December 23rd. Investors of record on Monday, December 8th were issued a $0.05 dividend. This represents a $0.20 annualized dividend and a yield of 0.4%. The ex-dividend date of this dividend was Monday, December 8th. Ralliant’s payout ratio is currently 15.75%.

About Ralliant

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.